Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer

被引:1
|
作者
Skoeld, Camilla [1 ]
Corvigno, Sara [2 ]
Dahlstrand, Hanna [2 ]
Enblad, Gunilla [1 ]
Mezheyeuski, Artur [3 ]
Sundstroem-Poromaa, Inger [4 ]
Stalberg, Karin [4 ]
Tolf, Anna [1 ]
Glimelius, Ingrid [1 ,5 ]
Koliadi, Anthoula [1 ]
机构
[1] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden
[2] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
[3] Vall dHebron Inst Oncol, Barcelona, Spain
[4] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden
[5] Karolinska Inst, Dept Med, Div Clin Epidemiol, Stockholm, Sweden
关键词
Ovarian cancer; Parity; Progesterone receptor; Tissue micro array; HORMONE-RECEPTOR EXPRESSION; RISK-FACTORS; PROGESTERONE; ESTROGEN; EPITHELIUM; APOPTOSIS; OVULATION; SURVIVAL;
D O I
10.1007/s10552-024-01876-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose High-grade serous ovarian cancer (HGSC) is the most common ovarian cancer subtype. Parity is an important risk-reducing factor, but the underlying mechanism behind the protective effect is unclear. Our aim was to study if the expression of hormones and proteins involved in pregnancy were affected by the woman's parity status, and if they may be associated with tumor stage and survival.Methods We evaluated expression of progesterone receptor (PR), progesterone receptor membrane component 1 (PGRMC1), relaxin-2, and transforming growth factor beta 1 (TGF beta 1) in tumor tissue from 92 women with HGSC parous (n = 73) and nulliparous (n = 19). Key findings were then evaluated in an independent expansion cohort of 49 patients. Survival rates by hormone/protein expression were illustrated using the Kaplan-Meier method. The independent prognostic value was tested by Cox regression, using models adjusted for established poor-prognostic factors (age at diagnosis, FIGO stage, type of surgery, and macroscopic residual tumor after surgery).Results HGSC tumors from parous women were PR positive (>= 1% PR expression in tumor cells) more often than tumors from nulliparous women (42% vs. 16%; p-value 0.04), and having more children was associated with developing PR positive tumors [i.e., >= 3 children versus nulliparity, adjusted for age at diagnosis and stage: OR 4.31 (95% CI 1.12-19.69)]. A similar result was seen in the expansion cohort. Parity status had no impact on expression of PGRMC1, relaxin-2 and TGF beta 1. No associations were seen with tumor stage or survival.Conclusion Tumors from parous women with HGSC expressed PR more often than tumors from nulliparous women, indicating that pregnancies might possibly have a long-lasting impact on ovarian cancer development.
引用
收藏
页码:1101 / 1109
页数:9
相关论文
共 50 条
  • [1] Risk of high-grade serous ovarian cancer associated with pelvic inflammatory disease, parity and breast cancer
    Stewart, Louise M.
    Spilsbury, Katrina
    Jordan, Susan
    Stewart, Colin
    Holman, C. D'Arcy J.
    Powell, Aime
    Reekie, Joanne
    Cohen, Paul
    CANCER EPIDEMIOLOGY, 2018, 55 : 110 - 116
  • [2] Prognostic features of the tumor microenvironment in high-grade serous ovarian cancer and dietary immunomodulation
    Mckenzie, Nathalie D.
    Ahmad, Sarfraz
    Awada, Ahmad
    Kuhn, Theresa M.
    Recio, Fernando O.
    Holloway, Robert W.
    LIFE SCIENCES, 2023, 333
  • [3] Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma
    Morse, Christopher B.
    Norquist, Barbara M.
    Harrell, Maria I.
    Agnew, Kathy J.
    Gray, Heidi J.
    Urban, Renata R.
    Garcia, Rochelle L.
    Goff, Barbara A.
    Swisher, Elizabeth M.
    GYNECOLOGIC ONCOLOGY, 2016, 143 (02) : 389 - 392
  • [4] Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior
    Reyes, Henry D.
    Devor, Eric J.
    Warrier, Akshaya
    Newtson, Andreea M.
    Mattson, Jordan
    Wagner, Vincent
    Duncan, Gabrielle N.
    Leslie, Kimberly K.
    Gonzalez-Bosquet, Jesus
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [5] High-Grade Serous Ovarian Cancer during Pregnancy: From Diagnosis to Treatment
    Vivod, Gregor
    Merlo, Sebastjan
    Kovacevic, Nina
    CURRENT ONCOLOGY, 2024, 31 (04) : 1920 - 1935
  • [6] The peritoneal tumour microenvironment of high-grade serous ovarian cancer
    Leinster, D. Andrew
    Kulbe, Hagen
    Everitt, Gemma
    Thompson, Richard
    Perretti, Mauro
    Gavins, Felicity N. E.
    Cooper, Dianne
    Gould, David
    Ennis, Darren P.
    Lockley, Michelle
    McNeish, Iain A.
    Nourshargh, Sussan
    Balkwill, Frances R.
    JOURNAL OF PATHOLOGY, 2012, 227 (02) : 136 - 145
  • [7] High-grade serous ovarian cancer: the clone wars
    Aleksander Salomon-Perzyński
    Magdalena Salomon-Perzyńska
    Bogdan Michalski
    Violetta Skrzypulec-Plinta
    Archives of Gynecology and Obstetrics, 2017, 295 : 569 - 576
  • [8] High-grade serous ovarian cancer: the clone wars
    Salomon-Perzynski, Aleksander
    Salomon-Perzynska, Magdalena
    Michalski, Bogdan
    Skrzypulec-Plinta, Violetta
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2017, 295 (03) : 569 - 576
  • [9] Drugs Repurposing in High-Grade Serous Ovarian Cancer
    Torralba, Manuel
    Farra, Rossella
    Maddaloni, Marianna
    Grassi, Mario
    Dapas, Barbara
    Grassi, Gabriele
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (42) : 7222 - 7233
  • [10] Association of clinical and laboratory variables with risk of venous thromboembolism in high-grade serous ovarian cancer
    Peippo, Maija H.
    Perkonoja, Katariina
    Isoviita, Veli-Matti
    Hynninen, Johanna
    Lassila, Riitta
    Carpen, Olli
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2025, 35 (02)